Summary of Southern Cross Gold Consolidated Conference Call Company Overview - Southern Cross Gold Consolidated is a dual-listed company on the TSX and ASX, focusing on the Sunday Creek Project in Victoria, Australia, which is recognized as one of the most exciting gold discoveries globally [1][20]. Key Points Project Development - The Sunday Creek Project has a multi-million ounce deposit with an average grade of 10 grams per tonne (g/t) [1]. - The project has achieved a hit rate of 6,900 gram meters or better over approximately 90 kilometers of drilling, indicating a strong potential for gold discovery [2]. - Currently, the company operates nine drilling rigs, with plans to increase to ten in October and eventually to 22 once a decline is permitted [2]. - The decline construction is expected to be completed by mid-next year, with a budget of approximately AUD 30 million (CAD 27 million) [9]. Financial Position - The company has $160 million in cash, fully funding its exploration and development programs [3]. - The shareholder base includes notable investors who own 30% of the stock, providing confidence in the company's direction [4]. Exploration and Resource Estimates - The exploration target is estimated to be between 2.2 to 3.2 million ounces, with a potential range of 8.3 to 10.6 g/t [6][14]. - The company is converting approximately 7.5 ounces from every meter drilled into the resource [7]. - The drilling program is extensive, with plans for 200 kilometers of drilling to establish a substantial resource [9]. Geological Insights - The geological structure includes a band of rocks about 100 meters wide, with extensive high-grade veins that have been historically mined [13][14]. - The average widths of the mineralized structures are between 2.3 to 3.8 meters, with some wider structures present [12]. Antimony Component - The project also has significant antimony resources, which are valuable due to recent export bans from China [17]. - Antimony is expected to aid in permitting the project, while gold will cover development costs [19]. Market and Regulatory Environment - Victoria has recently permitted four mines in the last six months, indicating a favorable regulatory environment for mining operations [20]. - The company emphasizes value creation per share in its decision-making processes, aiming to maximize shareholder returns [20]. Additional Insights - The company is in the early stages of its discovery, with only about 10% of the potential resource explored [19]. - The project is positioned strategically near major mining operations like Fosterville and Costafield, enhancing its exploration potential [12][19]. This summary encapsulates the critical aspects of Southern Cross Gold Consolidated's conference call, highlighting the company's promising project, financial stability, and strategic positioning within the mining industry.

Summary of Revolution Medicines Conference Call - September 10, 2025 Company Overview - **Company**: Revolution Medicines (NasdaqGS: RVMD) - **Focus**: Development of innovative targeted medicines for RAS addicted cancers, particularly pancreatic cancer, lung cancer, and colorectal cancer [4][5][46]. Key Points Industry Context - **Pancreatic Cancer**: - Third leading cause of cancer death in the U.S. with over 56,000 new cases annually [6][7]. - Over 90% of pancreatic adenocarcinoma (PDAC) tumors harbor a RAS driver mutation [6]. - Current five-year survival rate is only 3% despite existing therapies [7]. - Standard treatment involves cytotoxic chemotherapy, which has significant limitations [8][12]. Clinical Development - **Investigational Drugs**: - **Doraxonerasib**: The most advanced investigational RasOn inhibitor targeting RAS mutations [5][13]. - **Combination Therapy**: Evaluating doraxonerasib in combination with standard chemotherapy (GMP) for first-line treatment of metastatic PDAC [14][39]. Clinical Trial Insights - **Current Trials**: - **RAASILUTE-303**: A planned Phase III trial comparing doraxonerasib monotherapy and its combination with GMP against standard chemotherapy [40][49]. - **RAASILUTE-302**: Ongoing trial for second-line PDAC, expected to complete enrollment in 2025 [48][49]. Efficacy and Safety Data - **Monotherapy Results**: - In second-line PDAC, doraxonerasib showed a median overall survival (OS) of 13.1 months for RAS G12X and 15.6 months for all RAS mutants [20]. - Objective response rate (ORR) of 35% in RAS G12X and 29% in broader RAS mutant populations [17][18]. - **First-Line Treatment**: - In first-line PDAC, doraxonerasib monotherapy achieved an ORR of 47% and a disease control rate (DCR) of 89% [26][39]. - Combination with GMP showed an ORR of 55% and a DCR of 90% [39]. Safety Profile - **Adverse Events**: - Grade 3 or higher treatment-related adverse events (TRAEs) were reported at approximately 60% for the combination therapy [36]. - Common TRAEs included diarrhea, anemia, and liver enzyme elevations, with manageable rates [36][37][22]. Strategic Insights - **Market Positioning**: - Revolution Medicines aims to establish doraxonerasib as a new global standard of care for PDAC, addressing significant unmet medical needs [46][49]. - The company is focused on educating physicians about RAS inhibition to enhance uptake in community settings [104][106]. Future Directions - **Trial Design**: - The upcoming trials will evaluate the efficacy of doraxonerasib both as monotherapy and in combination with GMP, with a focus on overall survival as the primary endpoint [40][42]. - The company plans to reserve combination studies with FOLFIRINOX for mutant selective inhibitors due to the higher toxicity profile of FOLFIRINOX compared to GMP [44][45]. Conclusion - Revolution Medicines is making significant strides in the development of targeted therapies for RAS addicted cancers, particularly pancreatic cancer, with promising clinical data supporting the efficacy and safety of doraxonerasib. The company is poised to change the treatment landscape for PDAC through innovative trial designs and strategic market positioning [46][49].

Summary of BJ's Restaurants FY Conference Call Company Overview - **Company**: BJ's Restaurants (NasdaqGS: BJRI) - **Date of Conference**: September 10, 2025 Key Points Business Strategy and Performance - The CEO, Lyle Tick, emphasized the focus on strengthening the foundations of the business over the past year, aiming for a more consistent and sustainable operation [6][7] - The Pizookie Meal Deal, priced at $13, has become a significant traffic driver, accounting for approximately 15% of weekly business and nearly 20% on specific weekdays [10] - The company is exploring ways to evolve the Pizookie Meal Deal, including potential upgrades and new menu items [12][14] Menu Innovations - The company is revamping its pizza offerings, which are considered a core platform. The new pizza will launch in November, featuring a complete overhaul of the crust and ingredients to enhance quality [20][29] - The focus areas for the menu include pizza, Pizzookies, craft beverages, and shareables, with plans to streamline offerings by reducing the number of SKUs [31][32] - Seasonal items and customer feedback are being integrated into the menu strategy to keep offerings fresh and relevant [33] Operational Improvements - The company has implemented an Activity-Based Labor Model (ABLM) to optimize labor costs and improve guest satisfaction, with plans to expand this model to 20% of restaurants [38][40] - Operational metrics have shown improvement, with a focus on reducing errors in food preparation and order processing, leading to a double-digit decrease in food and beverage comps [36][37] Financial Outlook - Current store-level margins are projected to be in the mid-15% range, with potential for upside as operational efficiencies improve [43][44] - The CEO indicated that the focus is on growing sales and profit dollars rather than hitting specific percentage margin goals [45] Marketing Strategy - The marketing team has been effective in driving traffic through targeted campaigns, particularly around the Pizookie Meal Deal and new product launches [46][47] - Future marketing efforts will focus on building a consistent presence in social and influencer marketing, rather than competing on share of voice with larger brands [49] Store Development - The company is working on prototype stores to ensure that physical spaces reflect the brand's DNA and are adaptable to different market needs [53][55] - There is a focus on right-sizing stores based on market demand, with successful smaller footprint locations being identified [56] Off-Premise Business - The off-premise segment is seen as a growth opportunity, with plans to improve operational efficiency and menu offerings to better serve this channel starting in 2026 [58][60] Additional Insights - The company is committed to culinary excellence, particularly in pizza preparation, which has been a focus of employee training and operational standards [27] - The CEO expressed excitement about the potential for new product introductions and seasonal offerings to enhance customer engagement [33][59]

Summary of Novo Resources Conference Call Company Overview - Novo Resources is a dual-listed company on TSX and ASX, primarily focused on gold exploration and development, with an increasing interest in copper [2][5] - The company aims for a pathway to 1,000,000 ounces of gold and seeks standalone developments [2] Strategic Focus - The exploration strategy emphasizes core greenfields generation and late-stage exploration projects [4] - The company has not raised funds since its ASX dual listing IPO two years ago, indicating a strong balance sheet [3][5] - Current market capitalization is approximately AUD 40 million, with 3.55 million shares issued [5] Project Portfolio - The portfolio includes a mix of early-stage and advanced exploration projects, primarily located in Australia and Canada [4][9] - Key projects include: - **San Cristobal Mining**: A significant liquid investment supporting operations, valued at around AUD 20 million [6] - **New South Wales Projects**: - John Bull and Tipperbura, with promising drilling results and ongoing exploration [10][12] - **Belltopper Project in Victoria**: A small project with potential for high-grade resources, targeting 300,000 to 600,000 ounces [16][17] - **Pilbara Region**: Historically significant for the company, with ongoing exploration and a focus on gold and copper [18][19] Joint Ventures and Collaborations - A joint venture with Northern Star on a project adjacent to the Hemi project, with AUD 25 million committed for 50% ownership [20][21] - The company is exploring various greenfields areas, including Balabala and Sherlock Crossing, with historical mining significance [22][24] Exploration and Drilling Activities - Aggressive drilling programs are planned, with a focus on generating results quickly [30] - Recent drilling in Tipperbura yielded significant grades, indicating potential for multiple pits along a 22-kilometer zone [13] - The company is also exploring antimony targets in the Pilbara, with promising early-stage results [25][26] Financial Health and Shareholder Support - The company maintains a strong balance sheet with approximately AUD 7 million in cash [6] - A robust shareholder register includes notable investors like Northern Star and billionaire geologist Mark Creasy [7][29] Conclusion - Novo Resources is positioned as a high-quality exploration company with a diverse portfolio and a strong focus on advancing projects from greenfields to development stages [27][28] - The company is committed to aggressive exploration and aims to achieve significant discoveries that will enhance shareholder value [30]

Summary of Portillo's Conference Call Company Overview - **Company**: Portillo's - **Industry**: Restaurant and Food Distribution Key Points and Arguments Same-Store Sales and Traffic - Portillo's has revised its same-store sales outlook due to a challenging restaurant environment, indicating a shift in consumer behavior and a slowdown in traffic [3][4][5] - The management emphasizes the importance of operational excellence and a strong value proposition to drive traffic [4][5] Financial Guidance and Unit Openings - The company lowered its guidance for the full year, reflecting a decline in top-line performance [6][7] - The number of new restaurant openings has been reduced from 12 to 8 for the year, with 6 additional locations under construction [7][21] - For 2026, Portillo's plans to open 8 new restaurants, with a focus on improving unit economics [7][22] Strategic Board Additions - New board members, including Jack Hartung and Gene Lee, are contributing to the company's strategic reset and operational improvements [9] Value Proposition in Chicagoland - Portillo's believes its value proposition in Chicagoland is strong, particularly in quality and quantity, but acknowledges the need to reassess pricing strategies [11][12] Simplifying Operations - The company is discontinuing breakfast offerings to focus on core lunch and dinner traffic, alongside eliminating 18 to 20 other internal projects that do not drive transactions [19][18] Development Strategy - Portillo's is shifting its development strategy to ensure better unit economics, with a focus on reducing build costs for new restaurants [21][22][30] - The company is exploring financing options to lower capital burdens and improve cash-on-cash returns [30][31] Marketing and Brand Awareness - A new Chief Marketing Officer, Denise, has been hired to enhance brand communication and awareness, particularly in Texas [35][39] - Portillo's is actively engaging in grassroots marketing efforts in Texas, including food sampling and community involvement [39][40] Kiosk Deployment - The kiosk initiative has been successful, with ongoing improvements to enhance customer interaction [46] Supply Chain Management - Portillo's is managing commodity inflation effectively, particularly in beef, and is about 90% locked on beef lots for 2025 [47][49] Closing Remarks - The management reiterates a strong focus on driving traffic and achieving best-in-class unit-level economics, while also emphasizing the importance of eliminating non-essential projects [51] Additional Important Content - The company is optimistic about its cash flow generation and views the current phase as a reset rather than a decline [51] - Portillo's is exploring new restaurant formats, including inline locations, to adapt to changing market dynamics [24][25]

Summary of XORTX Therapeutics Webinar Company Overview - **Company**: XORTX Therapeutics (NasdaqCM:XRTX) - **Focus Areas**: Development of therapies for gout and autosomal dominant polycystic kidney disease (ADPKD) [9][12] Core Points and Arguments Gout Program - **Primary Focus**: Developing a formulation of oxypurinol for gout treatment, targeting allopurinol-intolerant patients [9][11] - **Market Opportunity**: Estimated at $700 million for allopurinol-intolerant gout patients, filling a gap left by febuxostat [11][15] - **Clinical Background**: The drug has a safe and effective clinical record established in over 800 patients [12] - **Regulatory Path**: Preparing to file a New Drug Application (NDA) within the next 12 to 14 months, with a review period of 9 to 12 months [19][26] - **Patient Demographics**: Approximately 50 million individuals have high uric acid levels, with 7 to 9 million diagnosed with gout [14] - **Pricing Strategy**: Projected launch price between $6,000 and $8,000 per patient per year [15] ADPKD Program - **Market Opportunity**: Estimated at $1 to $1.5 billion, with a focus on patients with high uric acid levels [12][24] - **Regulatory Path**: A single small registration trial may suffice for FDA approval [12] - **Current Treatment Landscape**: Tolvaptan is the only approved drug, costing $156,000 per patient per year, treating only 5% of patients [23][25] - **Potential Market Size**: Estimated peak net sales could exceed $1 billion by treating around 18,000 individuals [25] Development and Manufacturing - **Key Activities**: Preparing an Investigational New Drug (IND) application and conducting pharmacokinetic studies [10][20] - **Manufacturing Plans**: A year of stability testing is required before NDA filing [21][26] - **Team Expertise**: Strong developmental team with experience in drug development and commercialization [27][28] Additional Important Information - **Patent Protections**: Recent EU patent grants cover major countries, with U.S. patents extending through 2034 and additional layers through 2041 and 2043 [34][35] - **Commercialization Strategy**: Plans to establish manufacturing and distribution contracts in preparation for the product launch [36] - **Market Capitalization**: Currently around $4 million to $5 million, with potential for significant value creation as the NDA is submitted [38][39] Conclusion - **Investment Opportunity**: XORTX Therapeutics is positioned for growth with low-risk activities planned over the next 12 to 24 months, aiming to transition from a research-focused company to a revenue-generating entity [39]

Fortive (NYSE:FTV) FY Conference Summary Company Overview - **Company**: Fortive Corporation - **Date**: September 10, 2025 - **Speakers**: Olumide Soroye (President and CEO), Mark Okerstrom (CFO) Key Points Industry and Company Strategy - Fortive is executing the Fortive Axle Research Strategy aimed at accelerating profitable growth and shareholder value creation over the next few years [2][3] - The strategy focuses on three pillars: innovation, acceleration, and recurring customer value [2] - The company has a portfolio of 10 market-leading brands positioned in attractive segments, which are expected to deliver strong financial performance [3][4] Financial Outlook - Fortive is on track with the financial guidance provided during the Q2 earnings call, maintaining confidence in the medium-term financial outlook for 2026-2027 [3][4] - The company anticipates a gradual ramp in organic growth rates, targeting 3% to 4% growth for 2026-2027, with potential for better performance based on historical data [17][46] - Fortive generates approximately $1 billion in free cash flow annually, which will be utilized for share buybacks and selective bolt-on M&A [7][13] Capital Allocation - The capital allocation strategy is focused on maximizing shareholder returns, with an emphasis on share buybacks and high-quality bolt-on M&A opportunities [4][5] - Fortive is not pursuing large transformational deals and is maintaining a regular dividend [5][6] Customer Engagement and Growth - The company emphasizes customer intimacy and growth, leveraging its existing customer base of 100,000 to drive innovation and value [8][9] - A cultural shift towards closer customer relationships is being implemented to enhance growth potential [9] AI Integration - Fortive views AI as a significant opportunity, with 25% of the company focused on software products that can integrate AI capabilities to enhance customer value [15][16] - The company has established an AI Center of Excellence to lead in AI use cases across its operating brands [16] Market Dynamics and Headwinds - Fortive is experiencing some headwinds, including tariff uncertainties, healthcare reimbursement changes, and government spending fluctuations, which are expected to normalize over time [22][23][24] - The company is monitoring key metrics such as PMI, hospital procedure volumes, and construction indices to gauge market health [30] Segment Performance - The AHS segment experienced a decline in organic growth in Q2, attributed to hospital purchasing delays and reimbursement policy changes, but is expected to recover as these issues resolve [39][41] - Fluke, another segment, remains durable despite order delays, with 15% of its business now recurring models, contributing to its resilience [36][38] Competitive Landscape - Fortive's facility asset lifecycle management business is positioned uniquely with a focus on vertical-specific plays, leveraging proprietary data and a two-sided network [31][32] - The company competes in niche markets where it holds leadership positions, differentiating itself from competitors through its comprehensive service offerings [33][34] Future Guidance - Fortive remains confident in its financial framework for 2026-2027, projecting continued growth and margin expansion, with a focus on innovation and customer value [45][46][47] Conclusion Fortive is strategically positioned for growth with a clear focus on innovation, customer engagement, and disciplined capital allocation. The company is navigating current market challenges while maintaining a positive outlook for the future.

Summary of Donaldson Company Conference Call Company Overview - Donaldson Company is a 110-year-old filtration company based in Minnesota, with a diverse range of products and applications across global markets, supported by a strong R&D function [3][2]. Financial Performance - The company reported record top-line and bottom-line results for the recent fiscal year, with expectations for another record year in fiscal year 2026 [3][2]. - Historically, Donaldson has grown profits faster than revenues, achieving growth in nine out of the last ten years [4][3]. Aftermarket Business - The aftermarket segment, particularly mobile aftermarket solutions, has shown low single-digit growth driven by intellectual property and market share gains [7][5]. - Donaldson has a strong position in the OEM equipment side, which has allowed it to secure more market share through technology and availability [9][10]. - The company has invested in demand planning and inventory management to address supply chain challenges, contributing to reliability and share gains [10][9]. Market Dynamics - The mobile solutions market is cyclical, with expectations for high single-digit growth in on-road and mid-single-digit growth in off-road segments for fiscal year 2026 [14][15]. - The company anticipates a rebound in equipment demand, with historical patterns indicating significant recovery potential [15][16]. - Donaldson's content per vehicle varies by technology, with higher content in fuel cell applications compared to diesel engines [20][19]. Regulatory Environment - Regulatory changes, such as emissions regulations, have historically benefited Donaldson by increasing the demand for advanced filtration technologies [24][25]. - The company remains committed to technology development despite delays in regulatory timelines [22][23]. Industrial Solutions - The power generation segment is benefiting from increased demand for natural gas-powered solutions, particularly in data centers [26][27]. - Donaldson's utilization rates are high, with a solid backlog in production [26][27]. Life Sciences Segment - The life sciences business includes various units, with differing levels of maturity. The distrive segment is mature, while bioprocessing is still developing [35][36]. - The company expects steady growth in the distrive business and high single-digit growth in food and beverage segments [40][39]. Capital Allocation and M&A Strategy - Donaldson has a disciplined approach to capital allocation, focusing on internal investments and selective M&A opportunities, particularly in life sciences and industrial sectors [49][50]. - The company has a longstanding dividend policy and has increased dividends annually for 30 years [50][51]. Market Share and Growth Outlook - Donaldson is positioned as a leader in most of its markets, with expectations to continue outpacing market growth through strategic operational moves [62][63]. - The company sees potential for consolidation in fragmented markets, particularly in mobile solutions [63][64]. - Overall, Donaldson anticipates mid-single-digit growth and the ability to set new earnings records despite economic challenges [64][63]. Conclusion - Donaldson Company is well-positioned for future growth, leveraging its strong market position, technological advancements, and strategic investments to navigate challenges and capitalize on opportunities in various sectors [64][63].

Summary of Monro Inc. Conference Call Company Overview - **Company**: Monro Inc. - **Industry**: Automotive aftermarket services, specifically tire sales and vehicle maintenance - **Locations**: 1,115 locations across 32 states [3][4] Core Points and Arguments 1. **Turnaround Potential**: Monro is viewed as a company with strong turnaround potential due to its national presence and service-oriented business model, which is more valuable to customers compared to traditional retail [3][4] 2. **Financial Health**: The company has maintained profitability despite several years of negative comparable store sales, indicating strong fundamentals and sufficient liquidity to support turnaround efforts [3][4] 3. **Traffic Decline**: The automotive aftermarket industry has faced challenges, including a decline in customer traffic, which Monro aims to address through improved marketing strategies [4][6] 4. **Store Closures**: Monro closed 145 underperforming stores to streamline operations and improve overall performance, with minimal inventory write-off [8][9] 5. **Merchandising Improvements**: The company has hired a new merchandising leader to enhance product offerings and address tariff-related cost increases, aiming for better vendor collaboration [10][11] 6. **Digital Marketing Focus**: Monro has shifted to a more targeted digital marketing strategy, including paid search and social media, to attract repeat customers and drive traffic to stores [11][12] 7. **Customer Engagement**: The implementation of a call center and improved customer communication is expected to enhance service delivery and customer experience [13][14] 8. **Service Revenue Growth**: The company has seen significant increases in service-related revenue, particularly in ride control and brake services, indicating successful upselling strategies [15][16] 9. **Market Share Gains**: Monro gained market share in tire sales during the first quarter, despite industry challenges related to excess capacity [31][33] 10. **Balance Sheet Strength**: Monro reported a net bank debt of $64 million, indicating a conservative leverage position and sufficient cash flow to support capital allocation priorities [34] Additional Important Insights 1. **KPI Focus**: Key performance indicators for monitoring the turnaround include operating income, comparable store sales, earnings per share, and unit growth [35][36] 2. **Long-term Growth Strategy**: The company is considering expansion into new markets, particularly the Southwest, to drive future growth [36][38] 3. **Vendor Relationships**: Strong relationships with tire vendors are crucial for negotiating favorable terms and ensuring product availability [31][32] 4. **Tariff Considerations**: Potential tariffs on imported tires may impact pricing strategies and consumer choices, which the company is monitoring closely [32][33] This summary encapsulates the key points discussed during the conference call, highlighting Monro Inc.'s strategic initiatives, financial health, and market positioning within the automotive aftermarket industry.

Weave Communications (NYSE: WEAV) FY Conference Summary Industry Overview - Weave operates in the SMB healthcare sector, providing communication engagement software primarily for dental, optometry, veterinary, and specialty medical practices [4][10]. Core Points and Arguments 1. **AI Integration**: Weave is focusing on integrating AI into its workflows to enhance relevance in the healthcare sector. This includes automating appointment scheduling and payment collections, which are critical for practice growth and efficiency [4][5][12]. 2. **Market Demand**: SMB healthcare practices are primarily concerned with growing their practice, improving payment efficiency, and increasing profitability. Weave's solutions aim to address these needs through AI-driven automation [4][5]. 3. **Differentiation from Competitors**: Weave emphasizes its deep understanding of the healthcare industry, which allows it to effectively integrate with practice management systems. This is a significant advantage over horizontal AI tools that may not grasp the industry's nuances [7][8]. 4. **Adoption Rates**: There is a broad willingness to adopt AI across different healthcare sectors, but the pace varies. Dental practices, particularly those part of larger organizations, are leading in AI adoption compared to smaller, single-practitioner medical practices [9][10]. 5. **Total Addressable Market (TAM)**: Weave estimates a $3 billion TAM expansion related to scheduling solutions alone, indicating significant growth potential as more workflows are automated [12][13]. 6. **Market Penetration**: Weave has penetrated 10% to 15% of its mature verticals like dental and optometry, suggesting ample room for growth, especially in mid-market segments and specialty medical practices [14][15][20]. 7. **Future Growth Drivers**: Key growth areas include expanding into specialty medical, enhancing payment solutions, and leveraging AI for operational efficiency. The company aims to double its Annual Recurring Revenue (ARR) to $500 million, with operating margins projected between 15% to 20% [18][20][21]. 8. **Capital Allocation**: Weave has over $75 million in cash and is open to strategic acquisitions that align with its growth strategy, particularly those that enhance its capabilities and customer offerings [16][17]. Additional Important Insights 1. **Omnichannel Communication**: The future of AI in Weave's strategy includes developing omnichannel agents that can manage interactions across various platforms, enhancing patient engagement [28][29]. 2. **Customer Experience**: Weave is focused on creating a unified inbox for practices, allowing them to manage all patient interactions in one place, which is expected to significantly improve operational efficiency [28][29]. 3. **Internal AI Initiatives**: Weave is exploring AI applications internally, particularly in customer support and finance, to enhance operational efficiency and decision-making [25][26]. This summary encapsulates the key insights from Weave Communications' FY conference, highlighting the company's strategic focus on AI integration, market opportunities, and growth potential within the SMB healthcare sector.